Business
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
NEWARK, Calif., Feb. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., Feb. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on PN-943, the Company's oral, gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, at the 15th Congress of the European Crohn's and Colitis Organization (ECCO), which will take place Feb. 12-15, 2020, in Vienna.\n\n \n \n\n \nPresentation details: Title: PN-943, an Oral Alpha-4-Beta-7 Integrin Antagonist, Inhibits MAdCAM1-mediated Proliferation and Cytokine Release from CD4+ T-cells Independent of Trafficking Location: Messe Wien Exhibition and Congress Center, Hall C - Poster exhibition Date: Friday, Feb. 14 Time: 12:30-1:30 p.m. CET\nAbout PN-943\nPN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the treatment of inflammatory bowel disease. PN-943 is designed to offer the convenience of oral administration and the potential for improved safety and tolerability compared to antibody therapeutics administered by injection that target the alpha-4-beta-7 integrin pathway. PTG-100, a PN-943 analog, showed evidence of clinical and histological remission in patients with ulcerative colitis. PN-943 has completed Phase 1 development, demonstrating sustained target engagement with two weeks of daily administration.\nAbout Protagonist Therapeutics, Inc.\nProtagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia, polycythemia vera and hereditary hemochromatosis. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment ...